Patents by Inventor Eran Elinav
Eran Elinav has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240094224Abstract: Proxies for physiological states of tissue are provided. Accordingly, there are provided methods of determining host AMP landscape, establishing a profile indicative of tissue status, and identifying proxies for tissue status in AMP profiles of samples of secretions, exudates and/or excretions of the tissue. Also provided are methods for determination of disease severity and chronology.Type: ApplicationFiled: November 29, 2023Publication date: March 21, 2024Applicant: Yeda Research and Development Co. Ltd.Inventors: Eran ELINAV, Alon SAVIDOR
-
Publication number: 20230330051Abstract: A method of treating obesity in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent that specifically increases the amount of hexadecadienoate (16:2n6), N-acetylglycine, 1-palmitoyl-2-gamma-linolenoyl-GPC (16:0/18:3n6) and/or Hexanoylglycine; or an agent that decreases the amount of dimethylglycine (DMG) in the fecal metabolome of the subject. Agents suitable for same are also disclosed.Type: ApplicationFiled: September 20, 2021Publication date: October 19, 2023Applicant: Yeda Research and Development Co. Ltd.Inventors: Eran ELINAV, Leviel FLUHR, Uria MOR
-
Publication number: 20230223147Abstract: Method of predicting a response of a subject to food is disclosed. The method comprises: selecting a food to which a response of the subject is unknown; accessing a first database having data describing the subject but not a response of the subject to the selected food; accessing a second database having data pertaining to responses of other subjects to foods, the responses of the other subjects including responses of at least one other subject to the selected food or a food similar to said selected food; and analyzing the databases based on the selected food to estimate the response of the subject to the selected food.Type: ApplicationFiled: March 20, 2023Publication date: July 13, 2023Applicant: Yeda Research and Development Co. Ltd.Inventors: Eran SEGAL, Eran ELINAV
-
Patent number: 11610681Abstract: Method of predicting a response of a subject to food is disclosed. The method comprises: selecting a food to which a response of the subject is unknown; accessing a first database having data describing the subject but not a response of the subject to the selected food; accessing a second database having data pertaining to responses of other subjects to foods, the responses of the other subjects including responses of at least one other subject to the selected food or a food similar to said selected food; and analyzing the databases based on the selected food to estimate the response of the subject to the selected food.Type: GrantFiled: January 18, 2021Date of Patent: March 21, 2023Assignee: Yeda Research and Development Co. Ltd.Inventors: Eran Segal, Eran Elinav
-
Publication number: 20220362329Abstract: Methods of treating acute liver disease acute liver diseases are provided. Accordingly, there is provided a method of treating acute liver disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent capable of binding a component of a TLR-MYC signaling pathway selected from the group consisting of MYC, MYD88, TRIF and p38 and inhibiting expression and/or activity of the component.Type: ApplicationFiled: July 28, 2022Publication date: November 17, 2022Applicant: Yeda Research and Development Co. Ltd.Inventors: Eran ELINAV, Ido AMIT, Aleksandra Anna KOLODZIEJCZYK
-
Publication number: 20220184148Abstract: A method of determining tolerance to an agent in a healthy subject is disclosed. The method comprises: (a) determining a signature of a microbiome in a sample of the healthy subject who has been subjected to the agent or condition; and (b) comparing the signature of the microbiome of the healthy subject to at least one reference signature of a pathological microbiome, wherein when the signature of the microbiome of the healthy subject is statistically significantly similar to the reference signature of the pathological microbiome, it is indicative that the healthy subject is intolerant to the agent.Type: ApplicationFiled: January 20, 2022Publication date: June 16, 2022Applicant: Yeda Research and Development Co. Ltd.Inventors: Eran ELINAV, Eran SEGAL
-
Publication number: 20220184154Abstract: A method of treating bacterial vaginosis in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of a composition which comprises between three and twenty species of bacteria or a secretion thereof, wherein at least 70% of the bacteria of the composition are of the species Lactobacillus crispatus, thereby treating the bacterial vaginosis.Type: ApplicationFiled: February 28, 2022Publication date: June 16, 2022Applicants: Yeda Research and Development Co. Ltd., Hadasit Medical Research Services and Development Ltd.Inventors: Eran ELINAV, Yotam COHEN, Ahinoam LEV-SAGIE, Debra GOLDMAN-WOHL
-
Patent number: 11326147Abstract: A redirected Treg cell is endowed with specificity toward a selected target antigen or ligand. The cell contains a chimeric receptor polypeptide that is expressed in a single, continuous chain, with an extracellular recognition region displayed on the surface of the cell, a transmembrane region and an intracellular signaling region. The extracellular recognition region is specific for the selected target antigen or ligand. The intracellular signaling region includes a combination of T-cell signaling polypeptide moieties, which combination, upon binding of the extracellular recognition region to the selected target antigen or ligand, triggers activation of the redirected Treg cells to cause suppression of T-cell mediated immunity. Such redirected Treg cells may be used to suppress undesired activity of T effector cells thereby mediating an immune or inflammatory response.Type: GrantFiled: March 22, 2019Date of Patent: May 10, 2022Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Zelig Eshhar, Eran Elinav
-
Publication number: 20220031776Abstract: Disclosed herein are bacteriophage compositions and therapeutic uses thereof. The disclosure also relates to bacteriophage that are capable of lysing Klebsiella bacterial strains, e.g., strains that are associated with inflammatory bowel disease, and thereby capable of modulating disease.Type: ApplicationFiled: September 7, 2018Publication date: February 3, 2022Inventors: Kenya Honda, Koji Atarashi, Seiko Narushima, Eran Elinav, Rotem Sorek, Efrat Khabra, Hava Ben David, Eyal Weinstock, Sarah Pollock, Yulia Matiuhin, Naomi Zak
-
Publication number: 20210353611Abstract: A method of treating ALS in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount at least two metabolites.Type: ApplicationFiled: September 19, 2019Publication date: November 18, 2021Applicant: Yeda Research and Development Co. Ltd.Inventors: Eran ELINAV, Eran SEGAL
-
Publication number: 20210269860Abstract: A method of assessing whether a candidate subject is suitable for probiotic treatment is disclosed. The method comprises determining a signature of the gut microbiome of the candidate subject, wherein when the signature of the microbiome of the candidate subject is statistically significantly similar to a signature of a gut microbiome of a control subject known to be responsive to probiotic treatment, it is indicative that the subject is suitable for probiotic treatment.Type: ApplicationFiled: July 8, 2019Publication date: September 2, 2021Applicants: Yeda Research and Development Co. Ltd., The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical CenterInventors: Eran SEGAL, Eran ELINAV, Zamir HALPERN
-
Publication number: 20210260139Abstract: A method of analyzing the likelihood of weight regain in a subject who has reached a target weight by practicing a weight loss program is disclosed. The method comprises determining an amount or presence of at least one microbe and/or product thereof in the gut microbiome of the subject, wherein the amount of the at least one microbe is altered during a prior weight gain period of the subject to reach a level representative of an obese subject and further wherein the amount of the at least one microbe is retained at the level following the weight loss program, wherein the amount or presence of the at least one microbe or product thereof is predictive of weight regain.Type: ApplicationFiled: May 12, 2021Publication date: August 26, 2021Applicant: Yeda Research and Development Co. Ltd.Inventors: Eran ELINAV, Eran SEGAL
-
Publication number: 20210142905Abstract: Method of predicting a response of a subject to food is disclosed. The method comprises: selecting a food to which a response of the subject is unknown; accessing a first database having data describing the subject but not a response of the subject to the selected food; accessing a second database having data pertaining to responses of other subjects to foods, the responses of the other subjects including responses of at least one other subject to the selected food or a food similar to said selected food; and analyzing the databases based on the selected food to estimate the response of the subject to the selected food.Type: ApplicationFiled: January 18, 2021Publication date: May 13, 2021Applicant: Yeda Research and Development Co. Ltd.Inventors: Eran SEGAL, Eran ELINAV
-
Patent number: 10923230Abstract: Method of predicting a response of a subject to food is disclosed. The method comprises: selecting a food to which a response of the subject is unknown; accessing a first database having data describing the subject but not a response of the subject to the selected food; accessing a second database having data pertaining to responses of other subjects to foods, the responses of the other subjects including responses of at least one other subject to the selected food or a food similar to said selected food; and analyzing the databases based on the selected food to estimate the response of the subject to the selected food.Type: GrantFiled: May 15, 2019Date of Patent: February 16, 2021Assignee: Yeda Research and Development Co. Ltd.Inventors: Eran Segal, Eran Elinav
-
Publication number: 20200368322Abstract: A method of treating a disease associated with intestinal barrier dysfunction in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent which downregulates the amount of glucose in intestinal cells, with the proviso that the disease is not Diabetes or obesity. Other agents for treating diseases associated with intestinal barrier dysfunction are also disclosed.Type: ApplicationFiled: August 6, 2020Publication date: November 26, 2020Applicant: Yeda Research and Development Co. Ltd.Inventors: Benjamin GEIGER, Eran ELINAV, Inna GROSHEVA
-
Publication number: 20200331997Abstract: The present invention relates to methods for treating psoriasis and other indications by inhibiting leptin activity.Type: ApplicationFiled: July 2, 2020Publication date: October 22, 2020Applicant: ENZO THERAPEUTICS, INC.Inventors: YARON ILAN, ERAN ELINAV
-
Patent number: 10723797Abstract: The present invention relates to methods for treating psoriasis and other indications by inhibiting leptin activity.Type: GrantFiled: June 3, 2019Date of Patent: July 28, 2020Assignee: Enzo Therapeutics, Inc.Inventors: Yaron Ilan, Eran Elinav
-
Publication number: 20200206283Abstract: A method of improving the glucose response in glucose tolerant and intolerant subjects is provided. The method comprises providing to the subject probiotic compositions, or agents which specifically reduce bacterial species.Type: ApplicationFiled: November 14, 2019Publication date: July 2, 2020Applicant: Yeda Research and Development Co. Ltd.Inventors: Eran SEGAL, Eran ELINAV
-
Publication number: 20200056152Abstract: A redirected Treg cell is endowed with specificity toward a selected target antigen or ligand. The cell contains a chimeric receptor polypeptide that is expressed in a single, continuous chain, with an extracellular recognition region displayed on the surface of the cell, a transmembrane region and an intracellular signaling region. The extracellular recognition region is specific for the selected target antigen or ligand. The intracellular signaling region includes a combination of T-cell signaling polypeptide moieties, which combination, upon binding of the extracellular recognition region to the selected target antigen or ligand, triggers activation of the redirected Treg cells to cause suppression of T-cell mediated immunity. Such redirected Treg cells may be used to suppress undesired activity of T effector cells thereby mediating an immune or inflammatory response.Type: ApplicationFiled: March 22, 2019Publication date: February 20, 2020Inventors: Zelig Eshhar, Eran Elinav
-
Publication number: 20190382827Abstract: A method of determining the therapeutic effect of an agent, such as a metabolite, comprising: (a) exposing a pathological microbiome to the agent; and (b) comparing the signature of the pathological microbiome following the exposing with a reference signature of a healthy microbiome, wherein when the signature of the microbiome is statistically significantly similar to the healthy microbiome reference signature, it is indicative that the agent has a therapeutic effect on the microbiome. The agent may be provided to a subject having a pathological microbiome once it has been classified as therapeutic.Type: ApplicationFiled: July 30, 2019Publication date: December 19, 2019Applicant: Yeda Research and Development Co. Ltd.Inventors: Eran ELINAV, Eran SEGAL